2019 Maryland Code
Criminal Law
Title 5 - Controlled Dangerous Substances, Prescriptions, and Other Substances
Subtitle 4 - Schedules
§ 5-405. Schedule IV
(a) Schedule IV consists of each controlled dangerous substance:
(1) listed in this section;
(2) added to Schedule IV by the Department under § 5–202(b) of this title; or
(3) designated as a Schedule IV controlled dangerous substance by the federal government unless the Department objects under § 5–202(f) of this title.
(b) Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
(1) alfaxalone;
(2) alprazolam;
(3) barbital;
(4) bromazepam;
(5) butorphanol;
(6) camazepam;
(7) carisoprodol;
(8) cathine +/– (norpseudoepedrine);
(9) chloral betaine;
(10) chloral hydrate;
(11) chlordiazepoxide;
(12) clobazam;
(13) clonazepam;
(14) clorazepate;
(15) clotiazepam;
(16) cloxazolam;
(17) delorazepam;
(18) dexfenfluramine;
(19) dextropropoxyphene dosage forms;
(20) diazepam;
(21) dichloralphenazone;
(22) eluxadoline (viberzi);
(23) estazolam;
(24) ethchlorvynol;
(25) ethinamate;
(26) ethylloflazepate;
(27) fencamfamin;
(28) fenproporex;
(29) fludiazepam;
(30) flunitrazepam;
(31) flurazepam;
(32) halazepam;
(33) haloxazolam;
(34) ketazolam;
(35) loprazolam;
(36) lorazepam;
(37) lormetazepam;
(38) mebutamate;
(39) medazepam;
(40) mefenorex;
(41) methohexital;
(42) meprobamate;
(43) methylphenobarbital;
(44) midazolam;
(45) modafinil;
(46) nimetazepam;
(47) nitrozepam;
(48) nordiazepam;
(49) oxazepam;
(50) oxazolam;
(51) paraldehyde;
(52) petrichloral;
(53) phenobarbital;
(54) pinazepam;
(55) pipradrol;
(56) prazepam;
(57) quazepam;
(58) sibutramine;
(59) SPA (lefetamine);
(60) suvorexant (belsomra);
(61) temazepam;
(62) tetrazepam;
(63) tramadol;
(64) triazolam;
(65) zaleplon (sonata);
(66) zolpidem (ambien); and
(67) zopiclone (lunesta).
(c) Substances listed in Schedule IV include:
(1) a material, compound, mixture, or preparation that contains fenfluramine; and
(2) if its existence is possible:
(i) a salt of fenfluramine;
(ii) an optical, position, or geometric isomer of fenfluramine; and
(iii) a salt of an isomer of fenfluramine.
(d) Substances listed in Schedule IV include a material, compound, mixture, or preparation that contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
(1) diethylpropion;
(2) pemoline, including organometallic complexes and their chelates; and
(3) phentermine.
(e) By regulation, the Department may exempt from this section a compound, mixture, or preparation that contains a depressant substance listed in subsection (b) of this section if:
(1) the compound, mixture, or preparation contains an active medicinal ingredient that does not have a depressant effect on the central nervous system; and
(2) the admixtures are included in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances that have a depressant effect on the central nervous system.
(f) The Department may not add a substance to Schedule IV under § 5–202 of this title unless the Department finds that:
(1) the substance has a low potential for abuse relative to the substances listed in Schedule III;
(2) the substance has currently accepted medical use in treatment in the United States; and
(3) abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.
